Welcome to our dedicated page for First Tracks Biotherapeutics SEC filings (Ticker: TRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on First Tracks Biotherapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into First Tracks Biotherapeutics's regulatory disclosures and financial reporting.
First Tracks Biotherapeutics, Inc. reported second quarter 2026 results and updated progress across its pipeline. The company highlighted its CD122 antagonist ANB033, with a Phase 1b trial in celiac disease fully enrolled in Cohort 1 and ongoing enrollment in Cohort 2, and noted that the U.S. FDA granted Fast Track designation for ANB033 in celiac disease. Top-line data are reaffirmed for Q4 2026 for Cohort 1, Q1 2027 for Cohort 2, and Q3 2027 for a Phase 1b trial in eosinophilic esophagitis, with plans to start Phase 2 trials in two additional indications in H1 2027.
Cash, cash equivalents and investments totaled $168.0 million as of June 30, 2026, and the company reiterates a projected cash runway into Q2 2028, including expansion of ANB033 into two new indications. Research and development expenses were $25.6 million for the quarter, down from $39.3 million a year earlier, while general and administrative expenses rose to $9.3 million from $6.6 million, largely due to separation-related legal costs. Net loss for the quarter was $33.4 million, or $0.95 per share, compared with a net loss of $42.4 million, or $1.47 per share, in the prior-year period.
First Tracks Biotherapeutics, Inc. has updated insider ownership information for Chief Medical Officer Paul F. Lizzul, reflecting his holding of 16,667 performance stock units (PSUs). These PSUs relate to common stock and vest in two equal 50% tranches on March 12, 2027 and March 12, 2028, subject to his continued service.
First Tracks Biotherapeutics, Inc. updated an insider ownership report for Chief Business Officer Benjamin Stone to reflect holdings of 16,667 performance stock units (PSUs), each tied to common stock. The PSUs vest and settle over two years: 50% on March 12, 2027 and 50% on March 12, 2028, subject to his continued service on each vesting date.
First Tracks Biotherapeutics, Inc. updated its initial insider ownership report for President and CEO Daniel Faga to include 53,334 Performance Stock Units (PSUs) tied to common stock. The PSUs carry a stated exercise price of $0.0000 per unit. According to the vesting terms, 50% of the PSUs vest and settle on March 12, 2027 and the remaining 50% on March 12, 2028, in each case subject to Faga’s continuing service with the company on the applicable vesting date.
FMR LLC and Abigail P. Johnson report beneficial ownership of 2,054,127.49 shares of First Tracks Biotherapeutics Inc. common stock, representing 5.9% of the class. FMR LLC has sole voting power over 2,053,988.00 shares and sole dispositive power over 2,054,127.49 shares, with no shared voting or dispositive power reported.
Abigail P. Johnson is shown with sole dispositive power over 2,054,127.49 shares and no voting power, reflecting her control relationship with FMR LLC. One or more other persons may receive dividends or sale proceeds from these shares, but each such interest is stated to be under five percent of the outstanding common stock.
STONE BENJAMIN reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics, Inc. granted Chief Business Officer Benjamin Stone 60,492 performance-based restricted stock units (PSUs) on August 2, 2026, each representing one share of common stock. The PSUs were earned upon certified achievement of performance criteria and vest over two years: 50% on August 2, 2027 and 50% on July 1, 2028, subject to his continued service on each vesting date. Following this award, Stone directly holds 77,159 PSUs.
Lizzul Paul F. reported acquisition or exercise transactions in this Form 4 filing.
First Tracks Biotherapeutics, Inc. granted its Chief Medical Officer, Paul F. Lizzul, 60,492 performance stock units (PSUs) on August 2, 2026, after achievement of performance criteria certified by the Compensation Committee. Each PSU represents a conditional right to one share of common stock. The PSUs vest and settle over two years, with 50% vesting on August 2, 2027 and 50% on July 1, 2028, subject to his continued service, bringing his total PSUs to 77,159.
First Tracks Biotherapeutics, Inc. President and CEO Daniel Faga reported an acquisition of 193,576 performance stock units (PSUs), each representing a conditional right to receive one share of common stock. These PSUs were earned upon achievement of performance criteria certified on August 2, 2026, and vest 50% on August 2, 2027 and 50% on July 1, 2028, subject to his continued service. Following this award, Faga holds 387,156 PSUs in total.
BlackRock, Inc. reported a passive ownership position in First Tracks Biotherapeutics Inc. common stock. BlackRock beneficially owns 1,919,376 shares, representing 5.5% of the class. It has sole voting power over 1,886,631 shares and sole dispositive power over all 1,919,376 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of First Tracks Biotherapeutics’ outstanding common shares.
First Tracks Biotherapeutics, Inc. entered into a new sublease on June 15, 2026 with AnaptysBio, Inc. for approximately 45,057 rentable square feet at 10770 Wateridge Circle in San Diego, California.
The initial sublease term runs for 12 months, with an option to extend for up to an additional period ending no later than April 4, 2028, if the company gives at least three months’ prior written notice. The company may also terminate the sublease at any time during the term with three months’ prior written notice.
Monthly payments under the sublease equal the Basic Rent and Additional Rent AnaptysBio owes under the existing master lease, and the company is responsible for charges for services it requests. The sublease is subordinate to the master lease and will end if AnaptysBio’s lease or right to possess the premises terminates.